First-Line Oral Antibiotic for Community-Acquired Pneumonia
For an otherwise healthy adult outpatient with confirmed pneumonia and no comorbidities, prescribe amoxicillin 1 gram three times daily. This is the strongest recommendation from the 2019 ATS/IDSA guidelines 1.
Treatment Algorithm Based on Patient Risk Stratification
Healthy Adults Without Comorbidities
For patients without chronic heart, lung, liver, or renal disease; diabetes; alcoholism; malignancy; or asplenia:
First-line options (in order of recommendation strength):
- Amoxicillin 1 g three times daily (strong recommendation, moderate quality evidence) 1
- Doxycycline 100 mg twice daily (conditional recommendation, lower quality evidence) 1
- Macrolide (azithromycin 500 mg day 1, then 250 mg daily; OR clarithromycin 500 mg twice daily) - only if local pneumococcal macrolide resistance is <25% (conditional recommendation) 1
Adults With Comorbidities
For patients with any of the comorbidities listed above, you have two equally acceptable approaches:
Option 1 - Combination Therapy:
- Beta-lactam: amoxicillin/clavulanate (500/125 mg three times daily OR 875/125 mg twice daily OR 2000/125 mg twice daily) OR cephalosporin (cefpodoxime 200 mg twice daily OR cefuroxime 500 mg twice daily)
- PLUS macrolide (azithromycin or clarithromycin as above) OR doxycycline 100 mg twice daily
- Strong recommendation for combination with macrolide; conditional for combination with doxycycline 1
Option 2 - Monotherapy:
- Respiratory fluoroquinolone: levofloxacin 750 mg daily OR moxifloxacin 400 mg daily OR gemifloxacin 320 mg daily
- Strong recommendation, moderate quality evidence 1
Key Clinical Considerations
Why Amoxicillin is First-Line
The ATS/IDSA guidelines prioritize amoxicillin based on:
- High-dose oral amoxicillin demonstrates efficacy even in hospitalized CAP patients 1
- Targets the most common pathogen (Streptococcus pneumoniae) effectively
- Promotes antimicrobial stewardship by using narrow-spectrum therapy when appropriate
- Recent 2026 data from Sweden showed no difference in hospitalization or mortality between penicillin V and amoxicillin, supporting beta-lactam efficacy 2
Critical Pitfalls to Avoid
Macrolide resistance: Do not use macrolide monotherapy in healthy adults if your local pneumococcal macrolide resistance exceeds 25%. This is a conditional recommendation precisely because of rising resistance patterns 1. Recent 2025 data shows 31.2% of non-bacteremic pneumococcal pneumonia cases are nonsusceptible to at least one first-line outpatient agent 3, making appropriate antibiotic selection crucial.
Recent antibiotic use: If the patient has received antibiotics within the past 3 months, treat them as if they have comorbidities (use combination therapy or fluoroquinolone) even if otherwise healthy 4.
Atypical coverage debate: The guidelines do not mandate routine atypical coverage for all healthy outpatients. The evidence shows no mortality difference between regimens with and without atypical coverage in meta-analyses 1. Reserve broader coverage for patients with comorbidities or treatment failure.
Evidence Quality and Limitations
The 2019 ATS/IDSA guidelines acknowledge that RCTs comparing antibiotic regimens show no clear superiority of one agent over another, largely due to small sample sizes and rare mortality events 1. However, amoxicillin receives the strongest recommendation based on:
- Moderate quality evidence
- Proven efficacy in higher-risk inpatient populations that can be reasonably extrapolated to outpatients
- Antimicrobial stewardship principles favoring narrow-spectrum agents when appropriate
The guidelines explicitly state that inpatient and outpatient CAP share the same pathogens (except Legionella and gram-negative bacilli, which are rare in outpatients), justifying the use of inpatient efficacy data to inform outpatient recommendations 1.